Cancer drug dosing study aims to reduce severe side effects

NCT ID NCT07174453

Recruiting now Disease control Sponsor: University of Kansas Medical Center Source: ClinicalTrials.gov ↗

Summary

This study is testing whether giving standard cancer immunotherapies less frequently but at higher doses causes more severe side effects than giving them more frequently at lower doses. Researchers are enrolling 192 adults with various solid tumors who are eligible to receive pembrolizumab or nivolumab treatment. The main goal is to compare the rates of serious immune-related side effects between the two different dosing approaches.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOR MALIGNANCIES are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

The University of Kansas Cancer Center
RECRUITING

Westwood, Kansas, 66205, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

SOLID TUMOR MALIGNANCIES